Related Experiment Video
Updated: May 28, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
Interleukin 6 inhibition - RA and beyond
Robert S Woodrick1, Eric M Ruderman
1Northwestern University Feinberg School of Medicine Chicago, Illinois, USA.
Bulletin of the NYU Hospital for Joint Diseases
|November 1, 2011
Summary
Tocilizumab, an interleukin-6 (IL-6) receptor antibody, shows confirmed structural benefits for rheumatoid arthritis in diverse populations. Further research clarifies its efficacy and risks, expanding its use to other inflammatory conditions.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Tocilizumab (an IL-6 receptor antibody) is approved for rheumatoid arthritis (RA).
- Accumulating data guides its clinical application and risk assessment.
- Previous studies showed structural benefits in Japanese populations, now confirmed in others.
Purpose of the Study:
- To review current data on tocilizumab's use in rheumatoid arthritis.
- To explore its efficacy and safety in different patient groups.
- To assess its potential in other inflammatory diseases.
Main Methods:
- Analysis of clinical trial data.
- Review of post-approval data and emerging research.
- Examination of safety profiles and patient-reported outcomes.
Main Results:
- Structural benefits confirmed in non-Japanese RA populations.
- High-titer rheumatoid factor identified as a potential response marker.
- Clarified risks for toxicities like infection and GI perforation.
- Approved for systemic juvenile idiopathic arthritis; potential benefit in adult-onset Still's disease.
Conclusions:
- Tocilizumab is a valuable therapeutic option for RA with confirmed benefits.
- Ongoing research refines understanding of its efficacy, safety, and optimal use.
- Potential for IL-6 inhibition in other inflammatory conditions warrants further investigation.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...